Natural Capsules reported a standalone profit of ₹11.16 crore for FY26, but a consolidated net loss of ₹24.67 crore due to new API facility costs. The company sees FY26 as a 'testing year' focusing on API ramp-up.
Natural Capsules Navigates Investment Year with Standalone Profit, Consolidated Loss
Natural Capsules reported a standalone profit of ₹11.16 crore for the fiscal year 2025-26, while the consolidated entity registered a net loss of ₹24.67 crore. This divergence is attributed to significant depreciation and finance costs linked to its new API facility at Tumkur.
Reader Takeaway: Standalone profit stable; consolidated loss due to front-loaded investment costs.
What just happened
Natural Capsules Limited announced its financial results for FY2025-26, revealing a profitable standalone operation with ₹173.77 crore in revenue and ₹11.16 crore in profit after tax. However, on a consolidated basis, the company recorded a net loss of ₹24.67 crore on revenues of ₹187.20 crore. This consolidated loss is largely due to ₹17.14 crore in depreciation and finance costs associated with its new API facility.
Why this matters
The results highlight a company in a significant transition phase. While the core capsule business remains profitable and showed strong Q4 performance, the investment in the new API segment is creating short-term financial pressure on the consolidated books. Investors are watching the ramp-up of the API business and its ability to generate future revenue to offset these initial costs.
The backstory
FY26 was characterized by substantial capital expenditure for Natural Capsules, as it moved towards becoming an integrated pharmaceutical player. This involved commissioning a new HPMC capsule line and commencing commercial production at the Tumkur API facility through its subsidiary, Natural Biogenex. The company also navigated a temporary operational shutdown at its Puducherry capsule plant due to licensing issues, which have since been resolved.
What changes now
The company's focus shifts to stabilizing API production and increasing capacity utilization. A contract manufacturing agreement with FermBox Bio has been signed to this end. Management is also prioritizing obtaining international regulatory certifications like WHO GMP and USFDA for the API segment. No dividend was recommended for FY26, as the company conserves cash for expansion.
Risks to watch
Investors should monitor the global API pricing pressure, particularly from China, which could affect margins. The implementation of the New Labour Code 2025 is also expected to increase employee benefit costs. Crucially, the ability of the API segment to ramp up and become profitable will determine the reversal of consolidated losses.
Peer comparison
While specific peer financial data for FY26 is not provided in the filing, the API segment faces global overcapacity. Companies operating in this space are likely contending with similar pricing pressures. Natural Capsules' move to an integrated model, combining capsules and APIs, differentiates its strategy.
Context metrics (time-bound)
- FY26 Standalone Revenue: ₹173.77 crore
- FY26 Consolidated Revenue: ₹187.20 crore
- FY26 Standalone Profit After Tax: ₹11.16 crore
- FY26 Consolidated Loss After Tax: ₹(24.67) crore
- New HPMC Capsule Capacity: 20.25 BCPA
- Company Secretary Change: Pranjal Deshmukh resigned April 25, 2026; Akshay Dutta appointed May 27, 2026.
What to track next
Key metrics to follow include the capacity utilization rates at the Tumkur API facility, progress in securing USFDA and WHO GMP certifications, and the operational performance of the capsule division in Q1 FY27. Management's ability to effectively leverage the contract manufacturing agreement will be crucial.